

Urelumab

Catalogue No.: abx831220

Urelumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting TNFRSF9/CD137, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Urelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma. Urelumab is a fully human antibody that targets CD137. The antibody product was developed using Medarex's UltiMAB(R) technology and was the first UltiMAB- derived antibody in clinical development by Bristol-Myers Squibb under the December 2003 agreement with Medarex.

Target:	TNFRSF9/CD137
Clonality:	Monoclonal
Reactivity:	Human
Expression:	Recombinant
Tested Applications:	ELISA, WB
Host:	Human
Recommended dilutions:	Optimal dilutions/concentrations should be determined by the end user.
Conjugation:	Unconjugated
Isotype:	IgG4 Kappa
Form:	Liquid
Purity:	> 95%
Purification:	Purified from cell culture supernatants by Protein A/G chromatography.
Storage:	Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Buffer:	0.01 M PBS. pH 7.4.
CAS Number:	934823-49-1
Concentration:	Batch-dependent, typically between 0.5-2.0 mg/ml.

Datasheet

Version: 2.0.0

Revision date: 02 Apr 2025



Note:

THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.

For Reference Only